| Waldenström’s Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 |
| Publication Date |
Apr 2012 |
| Publisher |
GlobalData |
| Product Type |
Report |
| Pages |
79 |
| Single User License |
$
3995.00 |
| Site User License |
$
7990.00 |
| Corporate User License |
$
11985.00 |
|
|
Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase. |
Waldenström’s Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Waldenström’s Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Waldenstrom's Macroglobulinemia Therapeutics market. The report identifies the key trends shaping and driving the global Waldenstrom's Macroglobulinemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Waldenstrom's Macroglobulinemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Waldenstrom's Macroglobulinemia Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Waldenstrom's Macroglobulinemia Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Waldenstrom's Macroglobulinemia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Waldenstrom's Macroglobulinemia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Waldenstrom's Macroglobulinemia Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Waldenstrom's Macroglobulinemia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Waldenstrom's Macroglobulinemia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Waldenstrom's Macroglobulinemia Therapeutics market landscape? – Identify, understand and capitalize.
Companies MentionedAEterna Zentaris Inc
Allos Therapeutics, Inc
ELI Lilly
Genmab A/S
GlaxoSmithKline
Novartis
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Waldenström’s Macroglobulinemia Therapeutics - Introduction 7
2.1 Overview 7
2.2 Epidemiology 9
2.3 Etiology of Waldenström’s Macroglobulinemia 9
2.4 Pathophysiology 10
2.5 Symptoms of Waldenstrom’s Macroglobulinemia 11
2.6 Prognosis of Waldenström’s Macroglobulinemia 11
2.7 Diagnosis of Waldenström’s Macroglobulinemia 12
2.8 Treatment and Management Pattern of Waldenström’s Macroglobulinemia 14
2.8.1 Emergent Therapies 14
2.8.2 Current Therapies 14
2.8.3 Treatment Regime in Stages 16
2.9 GlobalData Pipeline Report Guidance 19
3 Waldenström’s Macroglobulinemia Therapeutics - Market Characterization 20
3.1 Waldenström’s Macroglobulinemia Therapeutics Market Size (2006-2011) - Global 20
3.2 Waldenström’s Macroglobulinemia Therapeutics Market Forecast (2011-2019) - Global 22
3.3 Waldenström’s Macroglobulinemia Therapeutics Market Size (2006-2011) - The US 24
3.4 Waldenström’s Macroglobulinemia Therapeutics Market Forecast (2011-2019) - The US 25
3.5 Waldenström’s Macroglobulinemia Therapeutics Market Size (2006-2011) - The UK 26
3.6 Waldenström’s Macroglobulinemia Therapeutics Market Forecast (2011-2019) - The UK 27
3.7 Waldenström’s Macroglobulinemia Therapeutics Market Size (2006-2011) - France 28
3.8 Waldenström’s Macroglobulinemia Therapeutics Market Forecast (2011-2019) - France 29
3.9 Waldenström’s Macroglobulinemia Therapeutics Market Size (2006-2011) - Germany 30
3.10 Waldenström’s Macroglobulinemia Therapeutics Market Forecast (2011-2019) - Germany 31
3.11 Waldenström’s Macroglobulinemia Therapeutics Market Size (2006-2011) - Italy 32
3.12 Waldenström’s Macroglobulinemia Therapeutics Market Forecast (2011-2019) - Italy 33
3.13 Waldenström’s Macroglobulinemia Therapeutics Market Size (2006-2011) - Spain 34
3.14 Waldenström’s Macroglobulinemia Therapeutics Market Forecast (2011-2019) - Spain 35
3.15 Waldenström’s Macroglobulinemia Therapeutics Market Size (2006-2011) - Japan 36
3.16 Waldenström’s Macroglobulinemia Therapeutics Market Forecast (2011-2019) - Japan 37
3.17 Drivers and Barriers for Waldenström’s Macroglobulinemia Therapeutic Market 38
3.17.1 Drivers for Waldenström’s Macroglobulinemia Therapeutics Market 38
3.17.2 Barriers for Waldenström’s Macroglobulinemia Market 38
3.18 Opportunity and Unmet Need Analysis 39
3.19 Key Takeaway 40
4 Waldenström’s Macroglobulinemia Therapeutics - Competitive Assessment 41
4.1 Overview 41
4.1.1 Strategic Competitor Assessment 41
4.2 Major Marketed Product Profiles in Waldenström’s Macroglobulinemia Therapeutics Market 42
4.2.1 Bortezomib in Combination with Dexamethasone and Rituximab 42
4.2.2 Fludarabine in Combination with Rituximab 42
4.2.3 Cyclophosphamide in Combination with Dexamethasone and Rituximab 43
4.2.4 Thalidomide in Combination with Rituximab 44
4.3 Key Takeaway 44
5 Waldenström’s Macroglobulinemia Therapeutics - Pipeline Assessment 45
5.1 Overview 45
5.2 Strategic Pipeline Assessment 45
5.3 Waldenström’s Macroglobulinemia Pipeline by Phases of Development 45
5.3.1 Waldenström’s Macroglobulinemia Therapeutics - Phase II Pipeline 46
5.3.2 Waldenström’s Macroglobulinemia Therapeutics - Phase I and II Pipeline 46
5.3.3 Waldenström’s Macroglobulinemia Therapeutics - Phase I Pipeline 47
5.4 Waldenström’s Macroglobulinemia Therapeutics - Pipeline by Mechanism of Action 48
5.5 Technology Trends Analytic Framework 49
5.6 Waldenström’s Macroglobulinemia Therapeutics - Promising Drugs Under Clinical Development 50
5.7 Molecule Profiles of Drugs under Clinical Development 51
5.7.1 KRX-0401 (Perifosine) 51
5.7.2 LY317615 (Enzastaurin) 51
5.7.3 LBH589 (Panobinostat) 52
5.7.4 Folotyn (Pralatrexate) 53
5.7.5 Arzerra (Ofatumumab) 53
5.8 Key Takeaway 54
6 Waldenström’s Macroglobulinemia Therapeutics - Clinical Trials Mapping 55
6.1 Clinical Trials by Country 55
6.2 Clinical Trials by Phase 56
6.3 Clinical Trials by Trial Status 57
6.4 Overall Sponsors 58
6.5 Prominent Sponsors 59
6.6 Top Companies Participating in Waldenström’s Macroglobulinemia Clinical Trials, 2011 60
7 Waldenström’s Macroglobulinemia Therapeutics - Strategic Assessment 61
7.1 Waldenström’s Macroglobulinemia Therapeutics - Implications for Future Market Competition 61
8 Waldenström’s Macroglobulinemia Therapeutics - Future Players 62
8.1 Introduction 62
8.2 Company Profiles 62
8.2.1 AEterna Zentaris Inc 62
8.2.2 Allos Therapeutics, Inc 63
8.2.3 ELI Lilly 65
8.2.4 Genmab A/S 66
8.2.5 GlaxoSmithKline 68
8.2.6 Novartis 69
8.2.7 Other Companies in the Waldenström Macroglobulinema Therapeutics Market 71
9 Waldenström’s Macroglobulinema Therapeutics - Licensing and Partnership Deals 72
10 Waldenström’s Macroglobulinemia Therapeutics - Appendix 73
10.1 Market Definitions 73
10.2 Abbreviations 73
10.3 Research Methodology 74
10.3.1 Coverage 74
10.3.2 Secondary Research 74
10.3.3 Forecasting 74
10.3.4 Primary Research 78
10.3.5 Expert Panel Validation 78
10.4 Contact Us 78
10.5 Disclaimer 78
10.6 Bibliography 79
List of Tables1.1 List of Tables
Table 1: Dosage Chart of Waldenström’s Macroglobulinemia Treatment Therapy 17
Table 2: Waldenström’s Macroglobulinemia Therapeutics Market, Seven Major Markets, Revenue ($m), 2006 - 2011 20
Table 3: Waldenström’s Macroglobulinemia Therapeutics Market, Major Markets, Forecast ($m), 2011 - 2019 22
Table 4: Waldenström’s Macroglobulinemia Therapeutics Market, The US, Revenue ($m), 2006 - 2011 24
Table 5: Waldenström’s Macroglobulinemia Therapeutics Market, The US, Forecast ($m), 2011 - 2019 25
Table 6: Waldenström’s Macroglobulinemia Therapeutics Market, The UK, Revenue ($m), 2006 - 2011 26
Table 7: Waldenström’s Macroglobulinemia Therapeutics Market, The UK, Forecast ($m), 2011 - 2019 27
Table 8: Waldenström’s Macroglobulinemia Therapeutics Market, France, Revenue ($m), 2006 - 2011 28
Table 9: Waldenström’s Macroglobulinemia Therapeutics Market, France, Forecast ($m), 2011 - 2019 29
Table 10: Waldenström’s Macroglobulinemia Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 30
Table 11: Waldenström’s Macroglobulinemia Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 31
Table 12: Waldenström’s Macroglobulinemia Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 32
Table 13: Waldenström’s Macroglobulinemia Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 33
Table 14: Waldenström’s Macroglobulinemia Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 34
Table 15: Waldenström’s Macroglobulinemia Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 35
Table 16: Waldenström’s Macroglobulinemia Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 36
Table 17: Waldenström’s Macroglobulinemia Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 37
Table 18: Waldenström’s Macroglobulinemia Therapeutics - Phase II Pipeline, 2011 46
Table 19: Waldenström’s Macroglobulinemia Therapeutics - Phase I and II Pipeline, 2011 46
Table 20: Waldenström’s Macroglobulinemia Therapeutics - Phase I Pipeline, 2011 47
Table 21: Waldenström’s Macroglobulinemia Therapeutics- Mechanisms of Action that Constitute the Others Section of the Pipeline 48
Table 22: Waldenström’s Macroglobulinemia Therapeutics - Most Promising Drugs Under Clinical Development, 2011 50
Table 23: Waldenström’s Macroglobulinemia Therapeutics - Clinical Trials by Country, 2011 55
Table 24: Waldenström’s Macroglobulinemia Therapeutics - Clinical Trials by Phase, 2011 56
Table 25: Waldenström’s Macroglobulinemia Therapeutics - Clinical Trials by Status, 2011 57
Table 26: Waldenström’s macroglobulinemia Therapeutics - Overall Sponsors, 2011 58
Table 27: Waldenström’s Macroglobulinemia Therapeutics - Prominent Sponsors, 2011 59
Table 28: Waldenström’s Macroglobulinemia Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 60
Table 29: AEterna Zentaris - Waldenström’s Macroglobulinemia Pipeline Products, 2011 63
Table 30: Allos Therapeutics - Waldenström’s Macroglobulinemia Pipeline Products, 2011 64
Table 31: Eli Lily - Waldenström’s Macroglobulinemia Pipeline Products, 2011 66
Table 32: Genmab - Waldenström’s Macroglobulinemia Pipeline Products, 2011 67
Table 33: GlaxoSmithKline - Waldenström’s Macroglobulinemia Pipeline Products, 2011 69
Table 34: Novartis - Waldenström’s Macroglobulinemia Pipeline Products, 2011 70
Table 35: Waldenström’s Macroglobulinemia Therapeutics Market - Future Players 71
Table 36: Waldenström’s Macroglobulinemia Deals 72
List of Figures1.2 List of Figures
Figure 1: Types of IgM Gammopathies 7
Figure 2: Progression of Waldenström’s Macroglobulinemia 8
Figure 3: Pathophysiology of Waldenström’s Macroglobulinemia 10
Figure 4: Treatment Pattern for Waldenström’s Macroglobulinemia 15
Figure 5: Treatment Regime for Waldenström’s Macroglobulinemia 16
Figure 6: Waldenström’s Macroglobulinemia Therapeutics Market, Seven Major Markets, Revenue ($m), 2006 - 2011 20
Figure 7: Waldenström’s Macroglobulinemia Therapeutics, Market Share ($m), 2011 21
Figure 8: Waldenström’s Macroglobulinemia Therapeutics Market, Major Markets, Forecast ($m), 2011 - 2019 22
Figure 9: Waldenström’s Macroglobulinemia Therapeutics Market, Seven Major Markets, Market Share ($m), 2019 23
Figure 10: Waldenström’s Macroglobulinemia Therapeutics Market, The US, Revenue ($m), 2006 - 2011 24
Figure 11: Waldenström’s Macroglobulinemia Therapeutics Market, The US, Forecast ($m), 2011 - 2019 25
Figure 12: Waldenström’s Macroglobulinemia Therapeutics Market, The UK, Revenue ($m), 2006 - 2011 26
Figure 13: Waldenström’s Macroglobulinemia Therapeutics Market, The UK, Forecast ($m), 2011 - 2019 27
Figure 14: Waldenström’s Macroglobulinemia Therapeutics Market, France, Revenue ($m), 2006 - 2011 28
Figure 15: Waldenström’s Macroglobulinemia Therapeutics Market, France, Forecast ($m), 2011 - 2019 29
Figure 16: Waldenström’s Macroglobulinemia Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 30
Figure 17: Waldenström’s Macroglobulinemia Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 31
Figure 18: Waldenström’s Macroglobulinemia Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 32
Figure 19: Waldenström’s Macroglobulinemia Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 33
Figure 20: Waldenström’s Macroglobulinemia Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 34
Figure 21: Waldenström’s Macroglobulinemia Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 35
Figure 22: Waldenström’s Macroglobulinemia Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 36
Figure 23: Waldenström’s Macroglobulinemia Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 37
Figure 24: Waldenström’s Macroglobulinemia Therapeutics Market, Drivers and Barriers, 2011 39
Figure 25: Opportunity and Unmet Need in the Waldenström’s Macroglobulinemia Therapeutics Market, 2011 40
Figure 26: Waldenström’s Macroglobulinemia Therapeutics - Strategic Competitor Assessment, 2011 41
Figure 27: Waldenström’s Macroglobulinemia Therapeutics - Pipeline by Phases of Development, 2011 45
Figure 28: Waldenström’s Macroglobulinemia Therapeutics - Pipeline by Mechanism of Action, 2011 48
Figure 29: Waldenström’s Macroglobulinemia Therapeutics - Technology Trends Analytics Framework, 2011 49
Figure 30: Waldenström’s Macroglobulinemia Therapeutics - Technology Trends Analytics Framework - Description, 2011 49
Figure 31: Waldenström’s Macroglobulinemia Therapeutics - Clinical Trials by Country, 2011 55
Figure 32: Waldenström’s Macroglobulinemia Therapeutics - Clinical Trials by Phase, 2011 56
Figure 33: Waldenström’s Macroglobulinemia Therapeutics - Clinical Trials by Status, 2011 57
Figure 34: Waldenström’s Macroglobulinemia Therapeutics - Overall Sponsors, 2011 58
Figure 35: Waldenström’s Macroglobulinemia Therapeutics - Prominent Sponsors, 2011 59
Figure 36: Waldenström’s Macroglobulinemia Therapeutics - Top Companies Participating in Clinical Trials, 2011 60
Figure 37: Implications for Future Market Competition in Waldenström’s Macroglobulinemia Therapeutics Market, 2011 61
Figure 38: Waldenström’s Macroglobulinemia Therapeutics - Pipeline by Company, 2011 62
Figure 39: Epidemiology Based Forecasting 75
Figure 40: Market Forecasting Model 77
| Title |
Date |
Price |
|
|
Jan 2013 |
$2000.00 |
|
| By Netscribes (India) Pvt. Ltd. |
| |
|
May 2012 |
$0.00 |
| Medical Devices Market in Russia 2009-2013 |
| By Infiniti Research Ltd |
| Medical devices comprise surgical equipment & appliances, diagnostic devices, X-ray, ophthalmic equipment, laboratory devices & diagnostics, dental equipment, medical disposables and others.The Russia ...Read More
|
|
Mar 2010 |
$1500.00 |
|
|
Jan 2013 |
$250.00 |
|
|
Jan 2012 |
$250.00 |
|
|
Jan 2010 |
$149.00 |
|
|
Jan 2010 |
$149.00 |
| 2010 U.S. HMO Medical Centers Industry Report |
| By Barnes Reports |
| The U.S HMO Medical Centers Industry report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2010 current and 20 ...Read More
|
|
Jan 2010 |
$149.00 |
|
|
Oct 2009 |
$149.00 |
|
|
Jan 2010 |
$149.00 |
|
| |
|
|
|
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9425069161
|
|
|
| |
|
| |
|
|
|
